Despite the limitations of this sequential BM analysis, including the low number of samples and distinct treatment modalities, these observations may suggest that disease progression and relapse in MDS is associated with an expansion of LSCs and GMPs, but not with CD44− HSCs. This evidence concerns the gene CD44 and myelodysplastic syndrome.